| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
0.040 | GeneticVariation | BEFREE | The BM probe not only enabled sensitive detection of two types of EGFR-associated point mutations located in GC-rich regions, but also successfully identified the BRAF V600E mutation in the serum from a thyroid cancer patient which could not be detected by the conventional sequencing method. | 28201758 | 2017 |
||||
|
0.040 | GeneticVariation | BEFREE | By contrast, evidences about sensitivity of thyroid carcinomas to BRAF inhibition are conflicting and it has been proposed that BRAF V600E thyroid carcinoma</span> cells are less sensitive to BRAF inhibitors due to activation of parallel signaling pathways. | 29033690 | 2017 |
||||
|
0.040 | GeneticVariation | BEFREE | When BRAF(V600E)-positive thyroid cancer cells were incubated with the specific BRAF inhibitor PLX4032, sensitivity to gefitinib was restored. | 23559083 | 2013 |
||||
|
0.040 | GeneticVariation | BEFREE | Epidermal growth factor receptor (EGFR) overexpression (EGFR-H) is implicated in thyroid carcinoma disease progression; however, the clinicopathologic significance of EGFR-H in tumors that harbor EGFR and/or v-Raf murine sarcoma viral oncogene homolog B1 (BRAF)(V600E) mutations is unknown. | 23746767 | 2013 |
||||
|
0.010 | GeneticVariation | BEFREE | Among them, the MET p.N375S and MLH1 p.V384D mutations, each was detected in two cases, and has rarely been found to be involved in thyroid cancer pathogenesis before. | 28757314 | 2018 |
||||
|
0.010 | GeneticVariation | BEFREE | In conclusion, our results suggest that the SNP HER2 I655V, but not the EGFR R497K, was associated with thyroid cancer risk. | 19860576 | 2009 |
||||
|
0.010 | GeneticVariation | BEFREE | In conclusion, our results suggest that the SNP HER2 I655V, but not the EGFR R497K, was associated with thyroid cancer risk. | 19860576 | 2009 |